U.S. markets closed

Pluristem Therapeutics Inc. (PSTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7300-0.0500 (-1.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close4.7800
Open4.7400
Bid4.7000 x 800
Ask5.0000 x 800
Day's Range4.7000 - 4.9600
52 Week Range4.3000 - 13.2900
Volume226,188
Avg. Volume759,050
Market Cap150.131M
Beta (5Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)-1.5840
Earnings DateFeb 15, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Butterfly, Trimble, 10X Genomics, Pluristem, Agora — What Cathy Wood's Ark Bought And Sold On Thursday
    Benzinga

    Butterfly, Trimble, 10X Genomics, Pluristem, Agora — What Cathy Wood's Ark Bought And Sold On Thursday

    Cathie Wood’s Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain stocks to see a spike in the after-hours session. Here’s a list of 7 stocks that the hedge fund bought and sold on Thursday. Trades For Ark Genomic Revolution ETF (NYSE: ARKG): Butterfly Network Inc (NYSE: BFLY): Bought 274,300 shares of the medical imaging devices company, representing about 0.049% of the ETF. Butterfly shares closed 3.33% lower at $16.27 on Thursday and were up 2.21% in the after-hours. It has a 52-week high of $29.13 and low of $9.34. 10X Genomics Inc (NASDAQ: TXG): Bought 79,573 shares of the gene sequencing biotechnology company, representing about 0.154% of the ETF. 10X shares closed 2.65% higher at $185.79 on Thursday. It has a 52-week high of $201.70 and low of $56.81. Phreesia Inc (NYSE: PHR): Sold 80,935 shares of the healthcare software services company, representing about 0.0465% of the ETF. Phreesia shares closed 5.82% higher at $55.13 on Thursday. It has a 52-week high of $81.59 and low of $17.27. Pluristem Therapeutics Inc (NASDAQ: PSTI): Sold 121,919 shares of the Israeli-based stemcell company, representing about 0.0063% of the ETF. Pluristem shares closed 0.84% higher at $4.81 on Thursday. It has a 52-week high of $13.29 and low of $3.09. Syros Pharmaceuticals Co (NASDAQ: SYRS): Sold 35,756 shares of the biopharmaceutical company that focuses on the development of treatments for cancer and monogenic diseases, representing about 0.003% of the ETF. Syros stock closed 1.27% lower at $7.38 on Thursday. It has a 52-week high of $15.65 and low of $5.14. Trades For Ark Innovation ETF (NYSE: ARKK): Trimble Inc (NASDAQ: TRMB): Bought 453,214 shares of the California-based hardware, software and services technology company, representing about 0.153% of the ETF. Trimble shares closed 3.79% higher at $80.74 on Thursday. Its has a 52-week high of $81.09 and low of $27.79. Trades For ARK Next Generation Internet ETF (NYSE: ARKW): Agora Inc (NASDAQ: API): Sold 104,001 shares of the software company, representing about 0.0789% of the ETF. Agora shares closed 6.86% higher at $53.72 on Thursday. It has a 52-week high of $114.96 and low of $33.60. See Also: Pinduoduo, Shopify, PayPal, LendingTree, JD.com — What Cathy Wood's Ark Bought And Sold On Wednesday See more from BenzingaClick here for options trades from BenzingaAnalyst Expects Tesla, GM To See EV Tax Credits Restored With Biden Kicking Off US 'Green Tidal Wave'Lordstown Motors Unveils Endurance Pickup Beta Versions© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • We're Keeping An Eye On Pluristem Therapeutics' (NASDAQ:PSTI) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Pluristem Therapeutics' (NASDAQ:PSTI) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
    GlobeNewswire

    Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

    HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-239890) previously filed with the U.S. Securities and Exchange Commission (the “SEC”), under the Securities Act of 1933, as amended. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About PluristemPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team. Forward-Looking StatementsThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the expected closing of the offering. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristem’s products may not be approved by regulatory agencies, Pluristem’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristem’s process; Pluristem’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristem’s patents may not be sufficient; Pluristem’s products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission. Pluristem Investor Contact Dana RubinDirector of Investor Relations972-74-7107194danar@pluristem.com